Novo Nordisk's September Tightrope: A Cardiology Setback, a Paediatric Milestone, and a Buyback That Keeps Running
Published on 09/09/2026 at 21:41 | Editorial boerse-global.de
The Danish pharmaceutical giant finds itself in an unusual position: its management is signalling confidence through relentless share repurchases, yet the market is punishing the stock with a persistence that technical analysts would call a damaged chart. Between 31 August and 4 September, Novo Nordisk bought back 1,055,000 B-shares, adding to a programme that has now accumulated 32,034,179 shares at an average price of 281.63 Danish kroner since its February start — a total outlay of roughly 9 billion kroner. The company's treasury now holds 46,074,876 of its own B-shares, equivalent to one percent of total capital.
That buying spree, however, has done little to arrest the slide in the company's market value. The shares currently trade at €38.41, down 1.5 percent on the day and 4.8 percent over the past week. Since the start of the year, the equity has shed 13 percent, leaving it a full 30 percent below the 52-week high of €54.86 touched in January. The 50-day moving average sits at €41.44, more than 7 percent above the current price — a level the stock would need to reclaim before any technical recovery could gain credibility.
A Pipeline Under Scrutiny
The market's nervousness is not hard to trace. The most immediate trigger was the decision to halt two late-stage trials of Ziltivekimab in heart failure, a call made by an independent data monitoring committee citing a "low probability" of achieving a divergent result. That setback follows a failed cardiovascular outcome readout in July, meaning a candidate once positioned as a growth driver beyond the GLP-1 franchise has been effectively hollowed out within a matter of months. Only one study — examining the drug in post-heart-attack patients — remains active, with results not expected until the first half of 2027.
The timing compounds the discomfort. The trial stoppage landed just as the company launched the oral version of Wegovy in Germany last Friday, the first EU market for the tablet formulation. Since that launch, the stock has fallen 4.2 percent. Citi, in a note dated 2 September and based on weekly IQVIA prescription tracking, points to slowing new-prescription trends for Novo's key GLP-1 obesity products — with the oral Wegovy variant a notable exception. The bank maintains a sell rating with a price target of 265 Danish kroner.
The Paediatric Bright Spot
Not every data point this week favoured the bears. Results from the Phase 3 STEP Young trial, which examined Wegovy in children under 12 over 68 weeks, showed that 40.4 percent of treated children no longer met the definition of obesity by the study's end, compared with zero percent in the placebo group. No new safety concerns emerged. The findings are slated for presentation at the ObesityWeek conference in Washington in November and could open a largely untapped age group for the company's lead product.
The company is also underscoring its geographic ambitions. On Wednesday, Novo Holdings, Novo Nordisk and Novonesis hosted the inaugural "Novo Group India Day" in Bengaluru. India is the only country outside Denmark where all four Novo entities operate, a marker of the region's strategic importance as healthcare spending accelerates.
The Buyback Signal
The repurchase programme itself is a statement of intent. The current 12-month scheme has a total envelope of 15 billion kroner and runs until early February 2027. A second, smaller programme — capped at 11.2 billion kroner with the same expiry — has so far acquired 17,275,000 shares for approximately 5.22 billion kroner. Management's willingness to keep buying through a weak tape suggests it views the equity as undervalued, even as external observers grow more cautious.
Just as Novo Nordisk's management is signalling confidence in its own assets, UK employers have a similar opportunity to shore up their position — by ensuring workplace risks are properly documented. A free Risk Assessment Toolkit with 41 ready-to-use templates and checklists can help you identify hazards before they become incidents. Download the free Risk Assessment Toolkit
What September 21 Will Decide
All these threads converge on a single date: the capital markets day on 21 September, when management must articulate how it intends to fill the Ziltivekimab-shaped hole in its pipeline. The bull case rests on semaglutide's expansion into new indications and the oral Wegovy tablet's European rollout, which could diversify revenue away from injectables. The bear case is that the prescription slowdown, if it persists, combined with a thinning pipeline beyond GLP-1, leaves the growth story standing on a narrower foundation than investors had assumed.
The elevated annualised volatility in the shares reflects that unresolved tension. Between now and the capital markets day, the stock remains a vehicle for investors who want to watch that debate play out in real time — with the buyback as a quiet counterweight to the noise.
